title: Intravenous BQ-123 and phosphoramidon reduce ventricular ectopic beats and myocardial infarct size in dogs submitted to coronary occlusion and reperfusion.
abstract: The aim of this work was to investigate the influence of endothelin on myocardial ischemia and reperfusion in anaesthetized dogs. Animals were submitted to left thoracotomy and 120 min of left anterior descending coronary occlusion, followed by 180 min of reperfusion. Arterial blood pressure and electrocardiogram (ECG) were recorded in order to analyze heart rate (HR)-pressure product and production of ectopic beats. Infarcted areas were identified by a macroscopic staining method and infarct size was expressed as percentage of risk zone. To inhibit the effects of endothelin in a group of animals, we administered intravenously an endothelin synthesis inhibitor (phosphoramidon) and in another group, an endothelin-1 A receptor blocker (BQ-123). Phosphoramidon decreased the HR-pressure product during reperfusion period, and both, phosphoramidon and BQ-123 decreased infarct size by 40% and the number of ventricular ectopic beats by 88% and 68%, respectively, as compared to the saline treated dogs. In conclusion, endothelin seems to play a deleterious role on the myocardium submitted to ischemia and reperfusion.
authors.affiliation: Departamento de Fisiología, Facultad de Medicina, Universidad de Valencia, Av. Blasco Ibáñez, 17, 46010 Valencia, Spain. antonio.alberola@uv.es
authors.forename: A M
authors.initials: AM
authors.lastname: Alberola Aguilar
authors.forename: F
authors.initials: F
authors.lastname: Revert
authors.forename: A
authors.initials: A
authors.lastname: Moya
authors.forename: J
authors.initials: J
authors.lastname: Beltrán
authors.forename: J
authors.initials: J
authors.lastname: García
authors.forename: E
authors.initials: E
authors.lastname: San Martín
authors.forename: S
authors.initials: S
authors.lastname: Sancho
authors.forename: L
authors.initials: L
authors.lastname: Such
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D003327:Coronary Disease / Q000188:drug therapy* / Q000503:physiopathology; D004285:Dogs; D004359:Drug Therapy, Combination; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000037:antagonists & inhibitors / Q000502:physiology; D006020:Glycopeptides / Q000494:pharmacology / Q000627:therapeutic use*; D007275:Injections, Intravenous; D009203:Myocardial Infarction / Q000188:drug therapy*; D015425:Myocardial Reperfusion / Q000379:methods; D010456:Peptides, Cyclic / Q000494:pharmacology / Q000627:therapeutic use*; D044022:Receptor, Endothelin A; D017466:Receptors, Endothelin / Q000502:physiology; D014693:Ventricular Fibrillation / Q000188:drug therapy / Q000503:physiopathology; D018879:Ventricular Premature Complexes / Q000188:drug therapy*
chemical_list: D000959:Antihypertensive Agents; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D006020:Glycopeptides; D010456:Peptides, Cyclic; D044022:Receptor, Endothelin A; D017466:Receptors, Endothelin; C072247:cyclo(Trp-Asp-Pro-Val-Leu); C008890:phosphoramidon